Ask VialBase
weight · loss

Cagrilintide

Also known as: AM833, NNC0174-0833
FDA: Not FDA-approved WADA: Not specifically listed

Cagrilintide (AM833 / NNC0174-0833) is a long-acting, once-weekly amylin analog developed by Novo Nordisk and a dual amylin and calcitonin receptor agonist (DACRA). It is the long-acting successor to Pramlintide (the first amylin analog, which required TID dosing) and is best known as the amylin half of CagriSema, its fixed-dose combination with Semaglutide. Mechanistically it sits in a different class from GLP-1/incretin drugs (Semaglutide, Tirzepatide, Retatrutide) — which is precisely why pairing it with semaglutide produces additive weight loss. Unlike most peptides in this vault, cagrilintide has a real, peer-reviewed human RCT program (Phase 1b → Phase 2 → Phase

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight ~3700
Half-life ~7 days ~159-195
CAS number —
Route Subcutaneous
02

Mechanism

Long-acting amylin analog and dual amylin and calcitonin receptor agonist (DACRA). Activates amylin/calcitonin receptor complexes (CTR + RAMP1/2/3 = AMY1/2/3) in the area postrema, dorsal vagal complex, and hypothalamus to increase satiety, slow gastric emptying, and suppress post-meal glucagon. Distinct from the GLP-1/GIP incretin pathway — the rationale for combining with semaglutide as CagriSema.

03

Dosing

DOSE RANGE 300–4500 mcg
FREQUENCY 1x weekly
CYCLE LENGTH Ongoing (titrate slowly over weeks to 2.4mg maintenance)

Phase 3 / CagriSema maintenance dose is 2.4mg weekly SubQ, reached by gradual titration to limit GI side effects. Phase 2 monotherapy tested 0.3-4.5mg. Amylin analogs are fibrillation-prone — formulation/handling quality matters. No approved consumer dose.

04

Stacking & interactions

Core pairing (= CagriSema). Amylin agonism + GLP-1 agonism = additive appetite suppression via parallel pathways. Drives ~20-23% weight loss vs ~16% sema alone.

Gut protection during GLP-1/amylin-mediated GI side effects (research context)

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Lipid Panel
  • Fasting Glucose
  • HbA1c
  • Fasting Insulin
  • Amylase
  • Lipase
DURING CYCLE
  • Fasting Glucose
  • HbA1c
  • Lipid Panel
  • Amylase
  • Lipase
POST-CYCLE
  • CMP
  • Lipid Panel
  • Fasting Glucose
  • HbA1c
Safety & Regulatory Status
FDA STATUS Not FDA-approved. Investigational. Best known as the amylin component of CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg). Novo Nordisk filed CagriSema NDA with FDA on 2025-12-18; decision expected ~late 2026. Stand-alone cagrilintide never submitted for approval.
WADA STATUS Not specifically listed (covered under S0 as non-approved substance)

Regulatory status for Cagrilintide may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.